Cornell researchers have created a groundbreaking vaccine platform that enhances protection against COVID-19 and influenza. Published in Science Advances, the study reveals that vaccinated mice exhibited 100% survival rates after exposure to the viruses, with no observable illness or tissue damage. Unlike current vaccines, this innovative platform is designed to be more effective and stable, potentially accommodating various viral antigens without cold-chain requirements. This technology addresses the limitations of existing vaccines, which typically require frequent booster doses and struggle with efficacy against multiple flu strains.
"One of the big moments was when we started achieving 100% survival and lack of clinical disease in all of the vaccinated mice following challenge with either SARS-CoV-2 or influenza virus."
"This is an exciting new modular technology that can accommodate glycoprotein antigens from many different viruses in a thermostable vaccine, making it possible to have dual, triple or more viral targets in the same vaccine."
Collection
[
|
...
]